Chronic thromboembolic pulmonary hypertension developed in a female patient with lupus erythematosus and secondary antiphospholipid syndrome


Cite item

Full Text

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the potentially curable forms of pulmonary hypertension, in which pulmonary thromboendarterectomy is the gold standard treatment. However, over the last decade, great attention has been given to a combined therapeutic approach including both drug therapy and surgical treatment and the application of endovascular technologies. This clinical case demonstrates the diagnostic difficulties of CTEPH and the opportunities of a comprehensive approach to therapy for the disease with mandatory assessment of preoperative surgical and medical treatment in order to improve the patient status and to prepare for surgery.

About the authors

G A Movsisyan

ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России

Москва, Россия

T V Martynyuk

ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России

Москва, Россия

K V Mershin

ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России

Москва, Россия

N M Danilov

ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России

Москва, Россия

M A Satybaldyeva

ФГБУ «НИИР им. В.А. Насоновой»

Москва, Россия

T M Reshetnyak

ФГБУ «НИИР им. В.А. Насоновой»

Москва, Россия

R S Akchurin

ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России

Москва, Россия

E L Nasonov

ФГБУ «НИИР им. В.А. Насоновой»

Москва, Россия

I Ye Chazova

ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России

Москва, Россия

References

  1. Lang IM, Pesavento R, Bonderman D, Yuan J-X. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. European Respiratory Journal. 2013;41:462-468. https://doi.org/10.1183/09031936.00049312
  2. Wolf M, Boyer-Neumann C, Parent F et al. Thrombotic risk factors in pulmonary hypertension. European Respiratory Journal. 2000;15:395-399. https://doi.org/10.1034/j.1399-3003.2000.15b28.x
  3. Moser KM, Auger WR, and Fedullo PF: Chronic major-vessel thromboembolic pulmonary hypertension. Circulation. 1990; 81:1735-1743. https://doi.org/10.1161/01.CIR.81.6.1735
  4. Легочная гипертензия. Под ред. Чазовой И.Е., Мартынюк Т.В. М.: Практика; 2015.
  5. Madani MM, Auger WR, Pretorius V et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. The Annals of Thoracic Surgery. 2012;94:97-103. https://doi.org/10.1016/j.athoracsur.2012.04.004
  6. Mizoguchi H, Ogawa A, Munemasa M et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circulation: Cardiovascular Interventions. 2012;5:748-755. https://doi.org/10.1161/CIRCINTERVENTIONS.112.971077
  7. Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal. 2015;46:903-975. https://doi.org/10.1183/13993003.51032-2015
  8. Hossein-Ardeschir Ghofrani, Andrea M D’Armini et al. for the CHEST-1 Study Group: «Riociguat for the Treatment of Pulmonary Arterial Hypertension». New England Journal of Medicine. 2013;369:319-329. https://doi.org/10.1056/NEJMoa1209657
  9. Решетняк Т.М. Системная красная волчанка. Ревматология. Клинические лекции. Под ред. проф. Бадокина В.В. М.: Литера; 2012:245-331.
  10. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis. 2006;4:295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
  11. Решетняк Т.М., Вавилова Т.В. Клинико-лабораторные критерии антифосфолипидного синдрома — что нужно знать практическому врачу (Лекция). Клиническая лабораторная диагностика. 2010;5:12-20.
  12. Решетняк Т.М., Раденска-Лоповок С.Г., Александрова Е.Н., Кондратьева Л.В. и др. Повреждение легких при антифосфолипидном синдроме. Общая реаниматология. 2005;1(5):34-43.https://doi.org/10.15360/1813-9779-2005-5-34-43
  13. Cervera R, Piette JC, Font J, Khamashta MA et al.; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis & Rheumatism. 2002;46(4):1019-1027. https://doi.org/10.1002/art.10187
  14. Erkan D, Pierangeli S, Lockshin M. Task Force Report on Antiphospholipid Syndrome Clinical Research. Antiphospholipid Syndrome. 2012:247-257. https://doi.org/10.1007/978-1-4614-3194-7_17
  15. Berkun Y, Elami A, Meir K et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. The Journal of Thoracic and Cardiovascular Surgery. 2004;127(2):414-420. https://doi.org/10.1016/j.jtcvs.2003.07.016
  16. Massoudy P, Cetin S, Thielman M et al. Antiphospholipid syndrome in cardiac surgery-an underestimated coagulation disorder? European Journal of Cardio-Thoracic Surgery. 2005;28(1):133-137. https://doi.org/10.1016/j.ejcts.2004.12.062

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies